Sherrington Robin - May 28, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: EVP, Strategy & Innovation
Signature: /s/ Cassandra Robinson, Attorney-in-fact
Stock symbol: XENE
Transactions as of: May 28, 2021
Transactions value $: -$95,938
Form type: 4
Date filed: 6/1/2021, 04:11 PM
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Options Exercise	$46.4K	+12.3K	+73.5%	$3.76^*	29.1K	May 28, 2021	Direct	F1
transaction	XENE	Common Shares	Tax liability	-$38.3K	-2.02K	-6.95%	$18.91	27.1K	May 28, 2021	Direct	F2
transaction	XENE	Common Shares	Options Exercise	$51.5K	+13.4K	+49.32%	$3.85^*	40.5K	May 28, 2021	Direct	F1
transaction	XENE	Common Shares	Tax liability	-$41.5K	-2.19K	-5.41%	$18.91	38.3K	May 28, 2021	Direct	F2
transaction	XENE	Common Shares	Sale	-$59.3K	-3.16K	-8.24%	$18.81	35.1K	May 28, 2021	Direct	F3
transaction	XENE	Common Shares	Sale	-$54.8K	-2.91K	-8.29%	$18.81	32.2K	May 28, 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-12.3K	-100%	$0.00^*	0	May 28, 2021	Common Shares	12.3K	$3.76	Direct	F1, F4, F5
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-13.4K	-100%	$0.00^*	0	May 28, 2021	Common Shares	13.4K	$3.85	Direct	F1, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2	Represents the closing price of the Company's common shares on May 27, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F3	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.22 to $19.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
F4	25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "January 2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the January 2011 Vesting Commencement Date.
F5	Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.
F6	1/3 of the shares subject to the Option vested on March 12, 2011 (the "March 2011 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the March 2011 Vesting Commencement Date over the following 4 years.